Shijiazhuang Yiling Pharmaceutical Co., Ltd.

SZSE:002603.SZ

21.72 (CNY) • At close October 26, 2023
Overview | Financials

Numbers are in millions (except for per share data and ratios) CNY.

2023202220212020201920182017201620152014201320122011201020092008
Revenue 10,183.18512,532.84110,116.7948,782.485,825.2944,814.5584,081.2673,820.1593,184.7522,921.1572,490.1621,648.6761,953.2111,649.321,632.331938.556
Cost of Revenue 4,595.1624,540.5723,680.9953,118.4132,106.2131,630.8251,303.9141,287.6981,164.4111,077.651830.502524.042617.691554.703636.807379.731
Gross Profit 5,588.0237,992.2696,435.7995,664.0673,719.0823,183.7332,777.3532,532.462,020.3411,843.5061,659.661,124.6341,335.5211,094.617995.524558.825
Gross Profit Ratio 0.5490.6380.6360.6450.6380.6610.6810.6630.6340.6310.6660.6820.6840.6640.610.595
Reseach & Development Expenses 819.2141,032.006792.163654.389390.746316.71217.441187.725154.631139.748139.379111.05182.174000
General & Administrative Expenses 185.71158.242165.913166.585114.683.05459.96356.646101.871.99766.51358.4534.223153.59101.90776.818
Selling & Marketing Expenses 2,704.6623,258.7143,434.0033,035.2682,227.0971,819.8741,600.9751,434.0531,159.5221,140.6731,133.453737.32638.011571.387528.441315.204
SG&A 3,167.0233,416.9563,599.9173,201.8542,341.6971,902.9281,660.9381,490.6991,261.3221,212.671,199.967795.77672.234724.976630.347392.022
Other Expenses 8.011576.866366.582322.967301.581-17.95-10.89514.3190.7253.85116.14128.1542.92523.77115.669-5.958
Operating Expenses 3,978.2265,025.8294,758.6614,179.2093,034.0242,499.4862,144.1411,904.011,541.8731,462.3161,424.781975.482846.671747.463650.546404.608
Operating Income 1,609.7982,829.5551,569.0711,438.036710.175718.953649.243623.689499.031409.993273.227188.221489.588345.719339.639150.371
Operating Income Ratio 0.1580.2260.1550.1640.1220.1490.1590.1630.1570.140.110.1140.2510.210.2080.16
Total Other Income Expenses Net 74.429-48.912-15.353-15.564-2.2916.7575.1359.2420.92129.3754.46267.08543.65421.6079.335-9.982
Income Before Tax 1,684.2262,780.6431,553.7181,422.472707.885701.004638.347637.691499.39410.56289.34216.236532.504368.761354.313144.235
Income Before Tax Ratio 0.1650.2220.1540.1620.1220.1460.1560.1670.1570.1410.1160.1310.2730.2240.2170.154
Income Tax Expense 339.909423.821212.086207.541104.841108.049101.562101.76572.58556.06445.04930.4378.43353.73656.79821.983
Net Income 1,352.3792,362.7561,343.8561,218.738606.501599.222540.705542.023430.491354.495244.291185.806454.071315.559297.183122.117
Net Income Ratio 0.1330.1890.1330.1390.1040.1240.1320.1420.1350.1210.0980.1130.2320.1910.1820.13
EPS 0.811.410.80.730.360.360.320.340.280.230.160.120.320.260.250.1
EPS Diluted 0.811.410.80.730.360.360.320.340.270.230.160.120.320.260.250.1
EBITDA 2,157.2063,375.6442,017.6251,767.512971.567958.673886.117857.085631.956466.122356.484288.89616.878421.636395.648178.394
EBITDA Ratio 0.2120.2690.1990.2010.1670.1990.2170.2240.1980.160.1430.1750.3160.2560.2420.19